Actavis seeks FDA approval to market generic Opana ER

Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that Actavis South Atlantic LLC, which was acquired by Watson in October, has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Oxymorphone Hydrochloride Extended-release Tablets.  Actavis' ANDA product is a generic version of the currently marketed formulation of Endo Health Solutions' Opana® ER, which is an opioid agonist indicated for the relief of moderate to severe pain in patients requiring continuous around-the-clock opioid treatment for an extended period of time.

Endo and Grunenthal GmbH filed suit against Actavis on January 18, 2013, in the U.S. District Court for the Southern District of New York seeking to prevent Actavis from commercializing its ANDA product prior to the expiration of certain U.S. patents.  The lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Actavis' ANDA for up to 30 months from the date the plaintiffs received notice of Actavis' ANDA filing or until final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities.

For the 12 months ending November 30, 2012, Opana® ER had total U.S. sales of approximately $512 million according to IMS Health data.


Watson Pharmaceuticals, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
You might also like... ×
Researchers use novel phage therapy to treat patient infected with multidrug-resistant bacterium